The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire has helped spotlight the growing virtual biotech model.
News that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model.
Fresh off a disappointing decision to jerk its marketing application for Replagal, Shire bounced right back with its announcement that it has scooped up the Bay Area biotech FerroKin BioSciences in a $325 million deal. Shire is paying $100 million upfront for FerroKin, with the rest offered in potential milestones.
Over the last few years, the virtual biotech model has become one of the hottest topics on the industry's bustling circuit of partnering and association gatherings. Every drug developer is being
With the help of investors Burrill & Company, Celgene, Clarus Ventures, MP Healthcare Venture Management and Healthcap Ventures, San Francisco-based FerroKin Biosciences has raised a $12 million